Vaccitech Revenue and Competitors

Oxford, UK

Location

$215.6M

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Vaccitech's estimated annual revenue is currently $15.5M per year.(i)
  • Vaccitech's estimated revenue per employee is $109,650
  • Vaccitech's total funding is $215.6M.

Employee Data

  • Vaccitech has 141 Employees.(i)
  • Vaccitech grew their employee count by 22% last year.

Vaccitech's People

NameTitleEmail/Phone
1
Co-FounderReveal Email/Phone
2
Head polymer chemistryReveal Email/Phone
3
Head CMC Project ManagementReveal Email/Phone
4
Senior Director, StatisticsReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Chief Business OfficerReveal Email/Phone
7
Director QualityReveal Email/Phone
8
Senior Director, ImmunologyReveal Email/Phone
9
Senior Director ResearchReveal Email/Phone
10
Associate DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.1M69-13%$16.5MN/A
#2
$264.2M1850-1%N/AN/A
#3
$51.9M401-10%$12.6MN/A
#4
$22.5M205-39%$63.8MN/A
#5
$1.1M21-19%$781.7KN/A
#6
$21.3M19033%N/AN/A
#7
$11.9M11710%N/AN/A
#8
$3.8M46-10%N/AN/A
#9
$8.8M86-16%N/AN/A
#10
$2.5M31-40%N/AN/A
Add Company

What Is Vaccitech?

Vaccitech is a spin-out company from the University of Oxford's Jenner institute, one of the oldest and most renowned vaccine research centres in the world. The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company's protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. This autumn, Vaccitech will begin a phase IIB efficacy study for a universal influenza vaccine in the over 65 population, and an extended phase I prostate cancer trial.

keywords:N/A

$215.6M

Total Funding

141

Number of Employees

$15.5M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vaccitech News

2022-04-17 - Reviewing Vaccitech (VACC) & Its Peers

Vaccitech (NASDAQ:VACC – Get Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it...

2022-03-30 - Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech is specialised in vaccine development that either prevents or cures a specific disease. Their main technology is based on simian...

2022-03-30 - Vaccitech Announces Notification of Milestone and Royalty ...

OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged...

2021-05-05 - VACCITECH PLC Vaccitech Announces Closing of $110.5 Million Initial Public Offering

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced ...

2021-05-04 - Vaccitech raises $110.5M in US debut

Vaccitech, the biotech startup behind the technology used to develop the Oxford-AstraZeneca COVID-19 vaccine, has raised $110.5 million in its US IPO. The UK-based company sold 6.5 million shares at a price of $17 each. Vaccitech's shares opened on the Nasdaq at $13.62 apiece, before rising to $ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M14214%N/A
#2
$28.3M1431%N/A
#3
$26.7M14731%N/A
#4
$7.5M15012%N/A
#5
$54M153-20%N/A